


Transglutaminase Newsletter February 2011

Drug Discovery Platform – Fluorescent Transglutaminase Antibodies

Dear valued customers,

Dear transglutaminase researchers in academia and industry,

Zedi  would like to highlight our new **services** and **products**:


Drug discovery platform

Zedira opens access to its transglutaminase-specific [drug discovery platform](#) composed by the modules compounds, screening, cell based assays and crystallization.

Please [contact](#) us for detailed information.

Fluorescent Transglutaminase Antibodies

Our polyclonal antibodies against TG1, TG2, TG3, TG6 and FXIII are now available with a **FITC** (**Fluorescein isothiocyanate**)-label, rendering them suitable e.g. for direct immunofluorescence (see picture) or FACS-experiments.



Stimulated CaCo2 cells expressing high levels of TG2 revealed by immunofluorescent staining with antibody **A028** (**FITC**-labeled polyclonal antibody against **human TG2**).

(20x magnification, courtesy of Walburga Dieterich, University Erlangen).

A028	FITC -labelled polyclonal antibody against human TG2 based on our TG2-antibody No. A014	Info	200 µg	345 €
A029	FITC -labelled polyclonal antibody against human TG1 based on our TG1-antibody No. A018	Info	200 µg	345 €
A030	FITC -labelled polyclonal antibody against human TG3 based on our TG3-antibody No. A015	Info	200 µg	345 €

A031 FITC-labelled polyclonal antibody against **human TG6** [Info](#) 200 µg 345 €
based on our TG6-antibody No. A017

A032 FITC-labelled polyclonal antibody against **h. factor XIII** [Info](#) 200 µg 345 €
based on our FXIII (A-subunit)-antibody No. A016

For detailed information concerning our products please refer to our web site (www.zedira.com). Should you have any questions or queries about our products, please do not hesitate to contact us: contact@zedira.com. We are continuously enlarging our product portfolio in order to fulfill researchers' requirements in the field of transglutaminase R&D.

The newsletter is sent to known interested parties only. If you do not want to receive the Transglutaminase Newsletter anymore, please click here to [unsubscribe](#) your mail address. In case that you know potential new interested colleagues, please forward this e-mail.

This newsletter is published by:

Zedira GmbH

Roesslerstr. 83

64293 Darmstadt

Germany

Phone: +49 6151 3251-00

Fax: +49 6151 3251-19

Web: www.zedira.com

E-mail: contact@zedira.com

© 2011, Zedira GmbH